0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

Plasma Lipid and Lipoprotein Levels with Continuous Subcutaneous Insulin Infusion in Type I Diabetes Mellitus

FREDERICK L. DUNN, M.D.; ANGEL PIETRI, M.D.; and PHILIP RASKIN, M.D.
[+] Article, Author, and Disclosure Information

Grant support: in part by grants AM18179, AM2700, 1-M01-RR0063, AM07307, and contract N01-M62219, National Institutes of Health; grant 549-8000-1, Veterans Administration Institutional Research Support Grant; and the American Heart Association. Dr. Dunn is a recipient of the Fellowship Award of the Juvenile Diabetes Foundation. Dr. Raskin was a Clinical Investigator at the Dallas Veterans Administration Medical Center.

Presented in part June 1981 at the 41st Annual Meeting of the American Diabetes Association.

▸Requests for reprints should be addressed to Philip Raskin, M.D.; Associate Professor, Department of Internal Medicine, University of Texas Health Science Center at Dallas; 5323 Harry Hines Blvd.; Dallas, TX 75235.


Dallas, Texas


© 1981 American College of PhysiciansAmerican College of Physicians


Ann Intern Med. 1981;95(4):426-431. doi:10.7326/0003-4819-95-4-426
Text Size: A A A

Plasma lipid and lipoprotein-cholesterol levels were measured in 10 insulin-dependent (Type I) diabetics taking their usual dose of conventionally administered insulin during 6 months of a continuous subcutaneous insulin infusion delivered with a small, portable, battery-powered pump. With this insulin delivery system we were able to provide near normal glucoregulation 24 hours a day for the entire study. This improved glucoregulation resulted in significant reductions in total plasma cholesterol and triglyceride, and very low density and low density lipoprotein-cholesterol levels within 2 to 4 weeks of treatment. These changes persisted for the entire 6 months of observation. High density lipoprotein-cholesterol levels rose significantly after 2 months of treatment and continued to increase during the 6-month study. These changes in plasma lipid and lipoprotein-cholesterol levels in response to treatment with continuous subcutaneous insulin infusion would favorably alter the predicted risk for the development of premature atherosclerosis in these patients.

Figures

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Related Point of Care
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)